REDWOOD CITY, California, 10-01-2024 — Biotricity Inc. (OTCQB:BTCY), Biotricity a leading innovative medical technology company, is transforming cardiac care with its cutting-edge solutions. Through its innovative platform and smart connected bio tech heart monitor devices, like Biocore, Biotricity gives healthcare providers and patients a powerful tool for continuous heart monitoring. Biocore is the only 3-lead advanced patch sized bio tech heart monitor in the world. Biotricity and its state-of-the-art suite of medical technology solutions help to improve patient outcomes, while simultaneously reducing healthcare costs and empowering individuals to take charge of their heart health.
As heart disease continues to be one of the leading causes of death globally, early detection and continuous monitoring of heart conditions is crucial, especially because 80% of heart attacks and strokes are preventable with early intervention. Traditional in-office ECGs only provide a brief snapshot of heart health, which can leave potentially critical issues undetected. Biotricity’s Biocore changes this by offering 24/7 non-invasive cardiac monitoring that tracks heart health continuously over longer periods of time. This constant stream of data allows healthcare providers to detect potential issues early, before they become life-threatening, enabling quicker intervention and improved outcomes.
Biocore was designed with healthcare providers and patients in mind. With its seamless integration into daily life, patients can wear Biotricity’s bio tech heart monitor without disrupting their normal activities. The heart data that Biocore continuously collects is securely transmitted for healthcare providers to access, ensuring that any abnormal heart rhythms or other heart issues are quickly detected. Early diagnoses lead to quicker disease management, more effective treatment, and fewer hospitalizations. The result is improved patient outcomes and reduced financial burdens on the healthcare system as well as the individual. For patients, Biocore provides invaluable peace of mind. The ability to monitor heart health continuously means that healthcare providers can take immediate action in response to detected irregularities. Whether it’s adjusting their medication or making lifestyle changes, this proactive approach to managing heart health enhances patients' ability to stay in control of their well-being. By using the bio tech heart monitor, patients and healthcare providers are empowered with the information they need to make informed decisions about proactive healthcare.
Chronic conditions such as heart failure can be managed more effectively at home through remote patient monitoring. Biotricity’s remote monitoring solutions help minimize the need for frequent in-person visits to healthcare providers. This reduces the strain on healthcare systems and allows healthcare providers to focus on direct patient care.
Biotricity is further improving the bio healthcare experience because its monitoring technology can be integrated with electronic health records (EHR) systems. This seamless integration provides healthcare providers with a comprehensive view of a patient’s heart health, making it easier to make accurate diagnoses, create personalized treatment plans, and collaborate more effectively within the healthcare team. Biotricity’s solutions make it easier for healthcare providers to deliver better care while reducing administrative burdens. As part of its ongoing mission to innovate and improve cardiac care, Biotricity is committed to expanding the capabilities of Biocore and its other products. With continuous advancements in its bio tech heart monitors, Biotricity ensures that patients and healthcare providers have access to the most advanced heart monitoring solutions. As bio healthcare continues to grow and evolve, Biotricity is poised to lead the way toward a healthier future for all. For more information about Biotricity and its innovative bio healthcare solutions, visit https://biotricity.com/.
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
Comments
0 comment